Retatrutide vs. Tirzepatide: The Triple Receptor Drug That May Beat Both

Tirzepatide (Mounjaro, Zepbound) was already a step change from semaglutide. The dual GLP-1/GIP agonism produced weight loss results — up to 22% body weight — that made semaglutide's 15% look modest by comparison.

Then Eli Lilly published Phase 2 results for retatrutide.

At 48 weeks, the highest dose produced 24.2% weight loss. Some trial participants approached 30%. These numbers had never been seen in a pharmaceutical weight loss trial. The obesity medicine community treated it as a potential inflection point.

Here's what retatrutide is, how it works, and what the data actually shows.

The Triple Receptor Mechanism

Retatrutide (development name LY3437943) is a single molecule that activates three receptors simultaneously:

GLP-1 receptor: Reduces appetite, slows gastric emptying, reduces glucagon secretion, improves insulin sensitivity. The mechanism shared by semaglutide and tirzepatide.

GIP receptor (glucose-dependent insulinotropic polypeptide): Enhances insulin secretion, improves insulin sensitivity in adipose tissue, works synergistically with GLP-1 for appetite suppression. The mechanism that makes tirzepatide more effective than semaglutide.

Glucagon receptor: This is the differentiator. Glucagon is typically thought of as a counter-regulatory hormone that raises blood glucose — the opposite of insulin. But glucagon receptor activation in this context has different effects: - Increases hepatic fat mobilization and oxidation (reduces liver fat) - Increases energy expenditure (thermogenic effect) - May enhance the appetite-suppressing effects of GLP-1 and GIP signaling

The glucagon component is why retatrutide is expected to produce weight loss beyond what dual agonism achieves. Adding a thermogenic mechanism to appetite suppression creates a two-pronged caloric deficit driver.

Phase 2 Results: The Numbers

The NEJM-published Phase 2 trial enrolled 338 patients with obesity (BMI ≥30) without diabetes. They received weekly subcutaneous retatrutide injections at various doses (1mg, 4mg, 8mg, 12mg) or placebo for 48 weeks.

Results at 48 weeks: - 1mg: 7.9% weight loss - 4mg: 17.3% weight loss - 8mg: 22.8% weight loss - 12mg: 24.2% weight loss - Placebo: 2.1% weight loss

At 48 weeks, 26% of patients in the 12mg group had lost ≥30% of body weight. These are remission-level outcomes — comparable to bariatric surgery — from a subcutaneous injection.

Liver fat (quantified by MRI) was dramatically reduced. Visceral fat reduction exceeded total fat reduction, consistent with the glucagon mechanism targeting hepatic and visceral depots.

Side Effects: The GI Trade-Off

The most common adverse events were gastrointestinal — nausea, diarrhea, vomiting — consistent with GLP-1 receptor agonists generally. Rates were dose-dependent and highest during titration.

Discontinuation due to adverse events: ~16% in the highest dose group. This is higher than tirzepatide Phase 3 rates (~5–7%) but not dramatically so. Phase 3 trials typically show improved tolerability from optimized titration schedules.

One potential concern with the glucagon component: glucagon stimulates gluconeogenesis, which could raise blood glucose. In Phase 2, fasting glucose was actually reduced (presumably from the dominant GLP-1 and GIP effects), but this remains an area for careful monitoring in Phase 3, particularly in patients with borderline metabolic function.

How Retatrutide Compares to Current Options

| | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Retatrutide (Phase 2) | |---|---|---|---| | Mechanism | GLP-1 agonist | GLP-1 + GIP agonist | GLP-1 + GIP + glucagon agonist | | Weight loss at 48–68 weeks | ~15% | ~22% | ~24% | | FDA approved | Yes | Yes | No (Phase 3) | | Availability | Yes | Yes | No | | Estimated approval | N/A | N/A | 2026–2027 | | GI side effects | Moderate | Moderate | Moderate-high |

When Could Retatrutide Be Available?

Phase 3 trials (TRIUMPH program) began in 2023–2024. Enrollment is complete; results are expected in late 2025 or 2026. If Phase 3 results confirm Phase 2 efficacy and establish an acceptable safety profile:

• FDA submission: 2026
• FDA review: 6–12 months standard review, potentially priority review
• Estimated approval: 2026–2027

This timeline puts retatrutide as a real near-term option, not a distant pipeline asset. For patients who start GLP-1 therapy now, it's plausible that their physician will be discussing a retatrutide transition at a future checkpoint.

What to Do Right Now

Retatrutide is not available today — not as an approved drug, not through compounding (it's not a drug shortage, it's an unapproved investigational compound).

For patients seeking maximum weight loss with currently available medications, tirzepatide (compounded or branded Zepbound) is the current standard. Its Phase 3 data showed up to 22% weight loss with a well-characterized safety profile.

The retatrutide data is exciting. But excitement about pipeline drugs shouldn't delay treatment with effective available options. Two years on tirzepatide at 22% weight loss produces real health outcomes now — not when the next drug arrives.

Marrow will update treatment options as new FDA-approved medications become available. For patients interested in clinical trials for retatrutide or other investigational agents, ClinicalTrials.gov maintains an updated list of enrolling studies.